Updated 9 November 2018
The HPTN presented 18 abstracts, seven oral presentations and 11 poster presentations, at the HIV Research for Prevention (HIVR4P) conference October 21-25, 2018 in Madrid, Spain. The presentations covered HPTN 067, HPTN 069, HPTN 074, HPTN 075, HPTN 077, HPTN 078 and the antibody mediated prevention (AMP) studies: HVTN 703/HPTN 081 and HVTN 704/HPTN 085.
In addition, HPTN data was featured in four satellite sessions including “State of the Art of HIV bNAbs for Prevention of HIV Infection” co-hosted by Myron Cohen, MD, HPTN co-principal investigator and Larry Corey, MD, HVTN principal investigator.
The second session, “Current State of Play: PrEP Implementation Update and Challenges” was co-chaired by Wafaa El-Sadr, MD, MPH, MPA, HPTN co-principal investor.
The third session, “Engagement of African MSM in HIV Prevention Research: Effective Recruitment and Retention” included a discussion on lessons learned from HPTN 075. Ken Mayer, MD, chair of the HPTN MSM Scientific Committee, will co-chair the session.
The fourth session, "It Only Hurts a Little: Long-Acting Injectables for HIV Prevention and Treatment" aimed to engage key stakeholders in a dialogue to mobilize, prepare, and plan for equitable and sustainable scale-up on long-acting antiretrovirals for key populations in different international resource settings. The session was co-chaired by Raphael Landovitz, MD, MSc, HPTN 077 and HPTN 083 protocol chair, and Steven Shoptaw, PhD, HPTN Executive Committee member.
Finally, Dr. Landovitz delivered a talk during the October 24 plenary session entitled, “Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis.”
_______________________________________________________________________________
HPTN at R4P Schedule of Events
Sunday, 21 October
Satellite Session - 15:00 - 18:00 - Marsella
Engagement of African MSM in HIV Prevention Research: Effective Recruitment and Retention
Chairs: Kenneth H. Mayer (Fenway Health, United States),
Sylvia Adebajo (Population Council, Nigeria)
Hosted by: International AIDS Vaccine Initiative (IAVI) and the US Military HIV Research Program (MHRP)
The purpose of this meeting is to convene researchers and other stakeholders to discuss how African MSM can be successfully engaged in planned HIV biomedical prevention trials, discuss various recruitment and retention strategies from Africa and develop best practices and tools to inform future research in Africa and other regions.
- Overview: HIV Prevalence, HIV Incidence, and Retention from Key African Studies of MSM – Joshua Kimani, University of Manitoba Kenya office
- Plenary: Including African MSM in HIV biomedical prevention research – opportunities, challenges – Anatoli Kamali, IAVI
- Lessons learned in recruitment and retention of African MSM
- Frederick Otieno, Nyanza Reproductive Health Society
- Elizabeth Wahome, KEMRI
- Zahra Parker, Research Manager, U.S. Military HIV Research Program-Nigeria
- Hannah Kibuuka, Research Physician, Makerere University Walter Reed Project
- Victor Akelo, KEMRI/CDC Senior Research Officer, Kisumu, Kenya
- Travis Sanchez, Emory University
- Strategic community engagement
- Sylvia Adebajo, Population Council, Nigeria
- Jeffrey Walimbwa, ISHTAR, Kenya
- Moderated Panel Q & A Discussion
- Closing remarks – Merlin Robb, U.S. Military HIV Research Program
Satellite Session - 16:00 - 18:00 - Estrasburgo
State of the Art of HIV bNAbs for Prevention of HIV Infection
Chairs: Larry Corey (Fred Hutchinson Cancer Research Center, United States)
Myron Cohen (University of North Carolina, United States)
Hosted by: HIV Vaccine Trials Network and HIV Prevention Trials Network
This session will cover current topics on the clinical development of broadly active neutralizing antibodies to HIV.
Monday, 22 October
Satellite Session - 8:30 - 11:30 - Bristol
Current State of Play: PrEP Implementation Update and Challenges
Chairs: Wafaa El-Sadr (Mailman School of Public Health, Columbia University, United States)
Rachel Baggaley (World Health Organization, Switzerland)
Hosted by: ICAP at Columbia University, World Health Organization (WHO), AVAC, CHAI and HIV Prevention Trials Network (HPTN)
This session will provide participants with an update on where we are with PrEP and future products, current understanding of the different approaches to oral PrEP implementation in low- and middle-income countries, the challenges faced and solutions found in efforts to scale-up programs. Panel discussions will elicit the perspectives from key experts and include debate on current controversies when considering and prioritizing PrEP implementation.
Satellite Session - 12:00 - 15:00 - Burdeos
It Only Hurts a Little: Long-acting Injectables for HIV Prevention and Treatment
Chairs: Steven Shoptaw (UCLA Medical Center, Santa Monica, United States)
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)
Hosted by: Center for HIV Identification, Prevention, and Treatment Services and the Center for AIDS Research at the University of California, Los Angeles, HIV Prevention Trials Network and the AIDS Clinical Trials Group
Ongoing clinical trials of long-acting injectable antiretroviral medications are being studied currently as both HIV prevention and maintenance of virologic suppression in HIV treatment. If safe and effective, long-acting agents have the potential to significantly impact the HIV epidemic by eliminating the requirement for daily oral dosing of antiretrovirals. This may have significant benefits for individuals living with or at risk for HIV, particularly among those who also have co-morbidities that complicate daily routinization of medication dosing, such as mental health and substance use disorders. Such individuals also commonly face structural issues, including housing instability and food insecurity, which can interfere with their capacity for daily oral medication adherence and persistence. With the first regulatory approvals of long-acting injectable antiretrovirals imminent, this interactive satellite session aims to facilitate efforts to mobilize, prepare and plan for culturally responsive, equitable and sustainable scale-up of long-acting injectable prevention and treatment agents for key populations in high-, middle- and low-income countries. The session will engage multidisciplinary stakeholders, including academic experts, policy researchers and civic society members, in a dialogue to articulate the challenges for implementation and uptake and, in particular, how acceptability and/or barriers may differ from those applicable to daily oral tablet formulations. The session will convene two moderated panels to discuss clinical, behavioral, policy and community considerations associated with the implementation of long-acting injectable antiretrovirals for prevention and treatment in the context of different international resource settings and key populations (for example, MSM, transgender women, pregnant and parenting cisgender women, youth).
Tuesday, 23 October
Oral Presentation - 13:00 - 14:30 - Londres
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV Uninfected Individuals: HPTN 077 ✤ B. Tolley / OA05.01 / 13:00-13:15
Poster Presentations - 17:30 - 19:30 - Poster Hall
Impact of Childhood Sexual Abuse Among Sub-Saharan African Men who Have Sex with Men and Transgender Women in HPTN 075 ✤ Y. Mbilizi / P03.57
Finding MSM who may be Potential Amplified HIV Transmitters: Results from HPTN 078 ✤ T. Gamble / P05.01
Retention in the Ongoing AMP Trials of VRC01, a Broadly Neutralizing Antibody (bnAb) to Prevent HIV in Women, MSM & Transgender (TG) People ✤ P. Andrew / P05.17LB
Differences by Wave of Respondent-driven Sampling Recruitment Among Gay Men and Other Men Who Have Sex With Men in 4 U.S. Cities: Results From HPTN 078 ✤ S. Baral / P14.43
Understanding HIV Transmission Dynamics and the Impact of Past HIV Interventions Among MSM in Baltimore: A Modelling Study for HPTN 078 ✤ R. Stilhol / P16.01
Interviewer Adjustment of Smart Pillbox Monitoring Did Not Improve Accuracy in Measuring Oral PrEP Adherence in HPTN 067 ✤ B. Dye / P25.05
Wednesday, 24 October
Oral Presentation - 10:30 - 12:00 - Bristol
HIV Incidence Among Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa: Findings From the Multi-country HPTN 075 Cohort Study ✤ T. Sandfort / OA10.04LB / 11:15 – 11:30
An Integrated Intervention to Increase ART and MAT Reduces Mortality Among PWID: Results From the HPTN 074 Randomized Trial ✤ K. Dumchev / OA10.06 / 11:45 – 12:00
Oral Presentation - 13:00 - 14:30 - Marsella
Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final Results ✤ R. Landovitz / OA15.06LB / 14:15 – 14:30
Poster Discussion - 16:45 - 17:30 - Oxford
Adaptive Non-Inferiority Margins in HIV Prevention Trials ✤ B. Hanscom / PD08.01 / 16:45 – 16:54
Poster Presentations - 17:30 - 19:30 - Poster Hall
Stigma, Self-Esteem and Depressive Symptoms in HIV-Infected Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa (HPTN 075) ✤ E. Hamilton / P03.46
Sexual Risk and Study Drug Detection in MSM Participants in a Phase II Study of Maraviroc (MVC) +/- Tenofovir DF (TDF) or FTC versus TDF/FTC for PrEP ✤ K. Mayer / P05.06
Antibody Mediated Prevention: Proof-of-Concept, Randomized, Blinded, Placebo-Controlled Trials to Assess Safety and Efficacy of VRC01 to Prevent HIV-1 ✤ S. Edupuganti / P05.18LB
Challenges to Collecting PrEP Adherence Data in the New York City (NYC) Site of the HPTN 067 Study ✤ S. Mannheimer / P25.10
Thursday, 25 October
Oral Presentation - 8:30 - 10:30 - Oxford
Beneficial Impacts Related to Participating in an International HIV Prevention Trial Involving People Who Inject Drugs ✤ J. Sugarman / 0A18.01 / 8:30-8:45
Standardized Metrics Can Reveal Region-Specific Opportunities in Community Engagement to Aid Recruitment in HIV Prevention Trials ✤ G. Broder / OA18.02 / 8:45 – 9:00
Oral Presentation - 10:30 - 12:00 - Marsella, Burdeos, & Estrasburgo
Potential Impact of Increased ART and PrEP Coverage on the HIV Epidemic Among MSM in Atlanta: Mathematical Modelling for HPTN 078 ✤ K. Mitchell / 0A23.06 / 11:45 - 12:00